259097-29-5Relevant academic research and scientific papers
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 73, (2010/02/11)
Hepatitis C virus inhibitors are disclosed having the general formula (I) wherein A, R2, R3, R', B and Y are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors
-
Page/Page column 31, (2010/02/12)
Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Substituted cycloalkyl P1' hepatitis C virus inhibitors
-
Page/Page column 125, (2010/02/06)
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Hepatitis C virus inhibitors
-
, (2008/06/13)
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS
-
Page 85, (2010/02/05)
The present invention relates to tripeptide compounds, compositionscontaining such compounds and methods for using such compounds for the treatment of heptitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositionscontaining such analogs and methods for using these analogs in the treatment of HCV infection.
Cyclopropyl building blocks for organic synthesis, 53([≠]). Convenient syntheses of novel α- and β-amino acids with spiropentyl groups
De Meijere, Armin,Ernst, Katrin,Zuck, Bernd,Brandl, Melanie,Kozhushkov, Sergei I.,Tamm, Markus,Yufit, Dmitrii S.,Howard, Judith A. K.,Labahn, Thomas
, p. 3105 - 3115 (2007/10/03)
Racemic spiropentylglycine (8) has been synthesized by sodium borohydride reduction of benzyl (E/Z)-2-chloro-2-spiropentylideneacetate (5- Bn), nucleophilic substitution of the chlorine in the product 6 with azide and hydrogenolytic deprotection of the resulting 7 (overall yield 15%). An alternative approach to 8 consisted of the coupling of the higher-order cuprate 10, generated by halogen-metal exchange from bromospiropentane (9), with the electrophilic glycine equivalent 11 followed by deprotection (overall yield 47%). Enantiomerically pure (1'-aminospiropentyl)acetic acid [(R)-16] (overall yield 16% from 5-Me) and 1-aminospiropentanecarboxylic acid [(R)-23] (29% from 5-Me) were obtained from the Michael adduct 14-Me of (4R,5S)4,5-diphenyloxazolidin-2-one (13) and methyl (E/Z)-2-chloro-2- spiropentylideneacetate (5-Me). Racemic 1-aminospiropentanecarboxylic acid (R/S-23) was prepared by rhodium-catalyzed addition of dimethyl diazomalonate to methylenecyclopropane and subsequent Curtius degradation of the half-ester 28 via the azide 29 (overall yield 14%). Upon standing in aqueous solution, 23 underwent complete rearrangement to the new 1-amino-2- methylenecyclobutanecarboxylic acid (24). The interesting derivative of azabicyclo[3.1.0]hexane-1-carboxylate 34 with an annelated spiropentane moiety and a β-amino acid fragment was incidentally obtained in a one-step intermolecular domino reaction starting with the addition of lithium benzylamide to methyl 2-chloro-2-cyclopropyhdeneacetate (32, 41% yield).
